Gamida Cell Ltd.
Harey Yehuda 54
P.O.B. 94
Savyon
56530
Tel: 03-534-7482
Fax: 03-534-3067
203 articles about Gamida Cell Ltd.
-
Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022
5/5/2022
Gamida Cell Ltd. today will share preclinical data at the International Society for Cell & Gene Therapy (ISCT) 2022, being held in San Francisco, CA, May 4-7, 2022 on GDA-301 and GDA-601.
-
Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast
5/3/2022
Gamida Cell Ltd. today announced that the company will host a conference call and live audio webcast on Tuesday, May 10, 2022, at 8:00 a.m. ET to review its first quarter 2022 financial results and provide an update on the company.
-
A roundup of last week's top clinical trial updates and news.
-
Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
4/27/2022
Gamida Cell Ltd. today announced updated one-year post-transplant data presented on omidubicel at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings (TCT), being held in Salt Lake City, UT, April 23-26, 2022.
-
Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201
4/26/2022
Gamida Cell Ltd. today announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application and removed the clinical hold for a cryopreserved formulation of GDA-201.
-
Gamida Cell reported that the FDA had lifted its clinical hold on its cryopreserved formulation of GDA-201. It expects to launch a Phase I/II drug trial for those indications this year.
-
Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
4/25/2022
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today announced that updated infection data on omidubicel in comparison to umbilical cord blood transplantation (UCB), was shared in an oral presentation at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings.
-
Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity
4/25/2022
Gamida Cell Ltd. today announced the results of a new study demonstrating the potential impact of access to omidubicel on health disparities in allogeneic hematopoietic stem cell transplant in a poster presentation at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings (TCT), being held in Salt Lake City, UT, April 23-26, 2022.
-
Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference
4/7/2022
Gamida Cell Ltd. announced that company management will present at the upcoming 21st Annual Needham Virtual Healthcare Conference on April 12, 2022 at 1:30 p.m. EDT.
-
Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
3/15/2022
Gamida Cell Ltd. today provided a business update and reported financial results for the year and quarter ended December 31, 2021.
-
Gamida Cell to Present Corporate Highlights at the Oppenheimer 32nd Annual Healthcare Conference
3/10/2022
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that company management will present its corporate highlights at the upcoming Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022 at 2:00 p.m. ET.
-
Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results and Webcast
3/8/2022
Gamida Cell Ltd. today announced that the company will host a conference call and live audio webcast on Tuesday, March 15, 2022, at 8:00 a.m. ET to review its fourth quarter and full year 2021 financial results and provide an update on the company.
-
Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel
2/9/2022
Gamida Cell Ltd. today announced that it has initiated the Biologics License Application (BLA) rolling submission process with the U.S. Food and Drug Administration for omidubicel.
-
On Thursday, Unity Biotechnology announced that it is cutting 50% of its workforce, mainly in the research department.
-
Gamida Cell Provides Key Program Updates and 2022 Financial Guidance
1/31/2022
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today provided key program and business updates.
-
Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors
1/31/2022
Gamida Cell Ltd. today announced the addition of Anat Cohen-Dayag, Ph.D., and Naama Halevi-Davidov, Ph.D., to its Board of Directors as Class II Directors.
-
Gamida Cell Provides Update on Omidubicel BLA Submission
1/19/2022
Gamida Cell Ltd. announced that following receipt of positive Type B meeting correspondence from the U.S. Food and Drug Administration (FDA) yesterday, the company plans to initiate a rolling Biologics License Application (BLA) submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant.
-
Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
1/7/2022
Gamida Cell Ltd. today announced eight presentations at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings (TCT) being held in Salt Lake City, UT, from February 2-6, 2022.
-
Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analysis for Omidubicel at 63rd ASH Annual Meeting
12/13/2021
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that two-year follow-up data for GDA-201, the company’s lead candidate in its NAM-enabled NK cell therapy pipeline, will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, being held in Atlanta, Georgia.
-
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
11/16/2021
Gamida Cell Ltd. today announced that company management will present its corporate highlights at the following upcoming virtual investor conferences: Evercore ISI 4th Annual HealthCONx Conference, November 30, 2021 with a presentation at 1:25 p.m. ET.